Cabot (NYSE:CBT) Price Target Cut to $83.00 by Analysts at UBS Group

Cabot (NYSE:CBT) had its price target lowered by equities research analysts at UBS Group from $93.00 to $83.00 in a research report issued on Monday,Benzinga reports. The firm presently has a “neutral” rating on the specialty chemicals company’s stock. UBS Group’s price target would indicate a potential upside of 11.13% from the company’s previous close.

A number of other research firms have also commented on CBT. Mizuho dropped their price objective on Cabot from $122.00 to $110.00 and set an “outperform” rating on the stock in a research note on Tuesday, January 7th. JPMorgan Chase & Co. dropped their price target on Cabot from $105.00 to $85.00 and set an “underweight” rating on the stock in a research report on Friday, February 21st. Finally, StockNews.com raised Cabot from a “hold” rating to a “buy” rating in a research report on Tuesday, April 1st. One analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $93.25.

Cabot Stock Down 2.3 %

CBT opened at $74.69 on Monday. The firm has a market cap of $4.05 billion, a P/E ratio of 9.92, a price-to-earnings-growth ratio of 0.74 and a beta of 1.04. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.29 and a current ratio of 2.00. The business has a 50 day moving average price of $84.10 and a 200 day moving average price of $96.66. Cabot has a twelve month low of $73.63 and a twelve month high of $117.46.

Cabot (NYSE:CBT) last posted its quarterly earnings data on Monday, February 3rd. The specialty chemicals company reported $1.76 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.74 by $0.02. Cabot had a net margin of 10.60% and a return on equity of 26.79%. Research analysts forecast that Cabot will post 7.57 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of CBT. Norges Bank bought a new position in shares of Cabot during the 4th quarter worth about $37,961,000. Millennium Management LLC lifted its stake in Cabot by 67.7% during the fourth quarter. Millennium Management LLC now owns 349,369 shares of the specialty chemicals company’s stock worth $31,901,000 after purchasing an additional 141,050 shares during the period. GAMMA Investing LLC boosted its holdings in Cabot by 10,385.0% during the first quarter. GAMMA Investing LLC now owns 141,338 shares of the specialty chemicals company’s stock valued at $11,751,000 after purchasing an additional 139,990 shares in the last quarter. Copeland Capital Management LLC grew its stake in shares of Cabot by 21.6% in the 4th quarter. Copeland Capital Management LLC now owns 761,372 shares of the specialty chemicals company’s stock valued at $69,521,000 after purchasing an additional 135,119 shares during the period. Finally, American Century Companies Inc. raised its holdings in shares of Cabot by 8.5% in the 4th quarter. American Century Companies Inc. now owns 1,323,347 shares of the specialty chemicals company’s stock worth $120,835,000 after buying an additional 103,380 shares in the last quarter. 93.18% of the stock is owned by institutional investors.

Cabot Company Profile

Cabot Corporation operates as a specialty chemicals and performance materials company. The company operates through two segments, Reinforcement Materials and Performance Chemicals. It offers reinforcing carbons that are used in tires as a rubber reinforcing agent and performance additive, as well as in industrial products, such as hoses, belts, extruded profiles, and molded goods; and engineered elastomer composites solutions.